GLI2 and plasma cell myeloma: The results showed that the expression levels of PTCH1, GLI2, Hes1, and SHH in RPMI 8226/R were greatly increased compared with the multiple myeloma drug-sensitive cell line RPMI 8226/S, while the expression level of GLI1 was notably decreased.